INS 2017: EU MDR Will Bring Changes, But Devices With Solid Data Will Still Clear Hurdle
A bumpy road may lie ahead for makers of high-risk implantable devices, such as neuromodulation technologies, with the advent of the EU Medical Device Regulation. Suzanne Halliday, from the notified body BSI, spoke to Medtech Insight from the International Neuromodulation Society annual meeting in Edinburgh, about key concerns with the regulation, and she offers advice to companies on how they can facilitate their transition towards the new regulatory environment.
You may also be interested in...
Are EU notified bodies raising the bar too high when it comes to assessing manufacturer compliance against the current Medical Devices Directive and Active Implantable Medical Devices Directive? Industry says it is challenged by notified bodies’ use of the latest EU clinical evaluation guidance document.
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.